China’s NMPA has approved Pfizer’s matazisimab (You Ruiting) for routine prophylaxis in hemophilia A or B patients with inhibitors, backed by pivotal BASIS data
The Centers for Medicare & Medicaid Services (CMS) announced a projected net savings of 44%, or $12 billion, on 15 widely used drugs for cancer and other chronic conditions, building on efforts to make prescriptions more affordable for Medicare beneficiaries. Under the Maximum Fair Price (MFP) negotiation policy, established as part of the Biden administration’s Inflation Reduction Act, CMS has negotiated lower prices for high-cost drugs, with these new prices set to take ef
